- Home
- XCUR vs SPRO Comparison
XCUR vs SPRO Comparison
Compare XCUR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCUR
- SPRO
- Stock Information
- Founded
- XCUR 2011
- SPRO 2013
- Country
- XCUR United States
- SPRO United States
- Employees
- XCUR N/A
- SPRO N/A
- Industry
- XCUR Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- XCUR Health Care
- SPRO Health Care
- Exchange
- XCUR Nasdaq
- SPRO Nasdaq
- Market Cap
- XCUR 74.1M
- SPRO 40.5M
- IPO Year
- XCUR N/A
- SPRO 2017
- Fundamental
- Price
- XCUR $11.38
- SPRO $0.58
- Analyst Decision
- XCUR
- SPRO Buy
- Analyst Count
- XCUR 0
- SPRO 4
- Target Price
- XCUR N/A
- SPRO $5.00
- AVG Volume (30 Days)
- XCUR 31.6K
- SPRO 116.9K
- Earning Date
- XCUR 06-16-2025
- SPRO 05-13-2025
- Dividend Yield
- XCUR N/A
- SPRO N/A
- EPS Growth
- XCUR N/A
- SPRO N/A
- EPS
- XCUR N/A
- SPRO N/A
- Revenue
- XCUR $500,000.00
- SPRO $47,977,000.00
- Revenue This Year
- XCUR N/A
- SPRO N/A
- Revenue Next Year
- XCUR N/A
- SPRO N/A
- P/E Ratio
- XCUR N/A
- SPRO N/A
- Revenue Growth
- XCUR N/A
- SPRO N/A
- 52 Week Low
- XCUR $1.44
- SPRO $0.51
- 52 Week High
- XCUR $36.00
- SPRO $1.72
- Technical
- Relative Strength Index (RSI)
- XCUR 51.56
- SPRO 31.32
- Support Level
- XCUR $9.81
- SPRO $0.64
- Resistance Level
- XCUR $11.58
- SPRO $0.75
- Average True Range (ATR)
- XCUR 1.00
- SPRO 0.05
- MACD
- XCUR 0.02
- SPRO -0.01
- Stochastic Oscillator
- XCUR 58.32
- SPRO 0.00
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.